Expression Status and Prognostic Value of m6A RNA Methylation Regulators in Lung Adenocarcinoma

Life

Xiaodong He¹  Rui Wang²  Xiuhong Li³  Zuojun Shen³  Jie Hu³  Zian Feng³ 

[1] Anhui Provincial Center for Clinical Laboratories, Hefei 230001, China;Deparment of Clinical Laboratory, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, China;Department of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China;

关键词: m⁶A methylation;    lung adenocarcinoma;    prognostic signature;    survival analysis;   

DOI  :  10.3390/life11070619

来源: DOAJ

【 摘 要 】

N⁶-methyladenosine (m⁶A) RNA modification is the most abundant modification method in mRNA, and it plays an important role in the occurrence and development of many cancers. This paper mainly discusses the role of m⁶A RNA methylation regulators in lung adenocarcinoma (LUAD) to identify novel prognostic biomarkers. The gene expression data of 19 m⁶A methylation regulators in LUAD patients and its relevant clinical parameters were extracted from The Cancer Genome Atlas (TCGA) database. We selected three significantly differentially expressed m⁶A regulators in LUAD to construct the risk signature, and evaluated its prognostic prediction efficiency using the receiver operating characteristic (ROC) curve. Kaplan–Meier survival analysis and Cox regression analysis were used to identify the independent prognostic significance of the risk signature. The ROC curve indicated that the area under the curve (AUC) was 0.659, which means that the risk signature had a good prediction efficiency. The results of the Kaplan–Meier survival analysis and Cox regression analysis showed that the risk score can be used as an independent prognostic factor for LUAD. In addition, we explored the differential signaling pathways and cellular processes related to m⁶A methylation regulators in LUAD.

【 授权许可】

Unknown